Business Wire

BLUEMATRIX

24.7.2024 10:01:29 CEST | Business Wire | Press release

Share
74% New Revenue Growth and C-Suite Hires for BlueMatrix

BlueMatrix, the world’s largest publisher of investment research, has announced that, since the start of 2024 and a strategic growth investment by leading software investment firm’s Thoma Bravo, new revenue has grown an impressive 74% on the same period last year. BlueMatrix is doubling down on its investment in its clients through a growth strategy that includes strengthening its leadership team with two major C-suite appointments. Its new Chief Financial Officer and Chief Revenue Officer have over 40 years of combined experience in scaling software companies within the financial services landscape.

Joining BlueMatrix’s leadership team, overseen by Chief Executive Officer and President Patricia Horotan and alongside Chief Operating Officer Mirko Consolascio, is Ben McFadden, appointed as Chief Financial Officer. He brings more than 15 years of enterprise software strategic finance expertise. He was previously Head of Finance at Nintex, a leader in global automation software, and Revalize, a quote-to-cash provider for manufacturing. His prior experience includes five years as a sell-side equity research analyst at Keybanc Capital Markets focused on infrastructure software.

Ben McFadden commented: “I witnessed BlueMatrix’s trajectory firsthand seven years ago as a sell-side equity analyst and now I get to be a part of this exceptional team. My focus is on maintaining our impressive 97% customer retention, enabled by our international expertise, industry-leading products, and outstanding service. With Thoma Bravo's strategic investment too, I believe the future for BlueMatrix is very bright indeed.”

Also joining BlueMatrix’s leadership team is Bryan North-Clauss, appointed as its Chief Revenue Officer. Most recently, he held the position of Chief Revenue Officer at Truv, after leading AlphaSense's financial services sales division, where he contributed to growing its annual recurring revenue by 350% and productivity per salesperson by 400%. Earlier in his career, Bryan held senior roles in fixed income sales at Deutsche Bank, Morgan Stanley, Citi, and Lehman Brothers. His career began as a founding member of software firm JobDirect.com, acquired by Korn/Ferry.

Bryan North-Clauss stated: “This is a pivotal moment for me to join BlueMatrix and contribute to its ambitious expansion plans following January’s strategic investment by Thoma Bravo. Six months in, my focus remains on reinforcing our market dominance and share in our core verticals. For instance, 75% of all sell-side research is published using the BlueMatrix platform, highlighting our strong product-market fit and commitment to delivering world-class service. Moving forward, we aim to invest further in our clients' success to drive future growth.”

BlueMatrix’s continued growth strategy will focus on moving to new markets, including Europe, APAC region, and South America, to deliver technical expertise and client experience to a new audience of global clients. There will also be increased focus on enhancing the innovation that optimises workflows, scalability, and deep integration across its entire product suite to meet the evolving needs of its worldwide client base.

Patricia Horotan, Chief Executive Officer and President of BlueMatrix, said: “Our plans to expand our platform and portfolio of products for existing and new clients alike will not only reinforce our world-leading status, but bring the most advanced investment solutions to new generations of investors. Working with my leadership team, and in partnership with Thoma Bravo, we are excited to take BlueMatrix to new markets and new audiences.”

Founded in 1999, BlueMatrix employs 147 people, with 42% in the US and 39% in Romania. Expansion into new markets, including Europe, APAC region, and South America, is planned for the second half of this year, highlighting the company's international growth.

BlueMatrix offers fully integrated, cloud-based solutions for the entire investment research production workflow, including content creation, compliance approval, distribution, hosting, and analytics. This comprehensive suite positions BlueMatrix as the only global platform covering the complete investment research lifecycle.

About BlueMatrix

BlueMatrix, the world’s largest publisher of investment research, is a pioneering SaaS provider connecting content publishers and readers. Since 1999, BlueMatrix has developed advanced research-creation and distribution software for the financial services sell side, serving over 800 banks and institutions worldwide and supporting the production and publishing of 1.4 million items annually.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240724453243/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NIQ Expands ConnectAI Charter Program with Mars Snacking22.10.2026 12:45:00 CEST | Press release

Mars joins a growing group of global companies working with NIQ forward-deployed engineers to bring proprietary consumer and market intelligence into enterprise AI workflows NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced Mars as a new ConnectAI Charter client, expanding the program’s growing roster of global companies working with NIQ to build the intelligence foundation for amplifying enterprise AI workflows. Through the ConnectAI Charter Program, NIQ forward-deployed engineers and data scientists are working with Mars to embed NIQ intelligence in the expansion of AI-enabled workflows across its business. The engagement focuses on connecting NIQ data, models, and business context with Mars’ AI ecosystem to help reduce the distance between data and decision-making. Together, they are tackling use cases like conversational analytics and harmonized product data to lay the foundation for future use cases. “As we expand the use of AI across our business, we

Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer22.10.2026 12:18:00 CEST | Press release

An independent, blinded evaluation of 620 patients from the phase III PANTHER trial identified nearly one-quarter as Low Risk despite clinically high-risk breast cancer, with favorable ten-year outcomes. Spotlight Medical, a company developing AI-powered prognostic tests in oncology, today announced results from an independent evaluation of myStage Dx, its CE-IVDR-marked test for assessing recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer. The study was conducted by researchers at Karolinska Institutet in Sweden. Independent, Blinded Evaluation Using Phase III Trial Data The study used data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dxpredictions were generated blinded to clinical outcomes. Researchers at Karolinska Institutet linked the predictions to patient outcomes and independently assessed prognostic performance according to a prespecified p

Zoomtopia: Zoom lancerer nye AI-funktioner22.10.2026 12:13:00 CEST | Pressemeddelelse

Zoom vil forkorte vejen fra mødebeslutning til udført arbejde. På konferencen Zoomtopia præsenterer virksomheden Unified Context Layer – et fælles informationslag, der forbinder samtaler, dokumenter og data, så AI kan forstå sammenhængen og hjælpe med de næste skridt. Samtidig lanceres flere nye AI-produkter og -funktioner, der skal gøre det lettere at omsætte diskussioner og beslutninger til handling. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261021318859/da/ I møder og samtaler træffes vigtige beslutninger, og virksomheder får værdifuld indsigt i deres kunder. En kundedialog kan begynde i et møde, fortsætte i telefonen og derefter gå over i en chat. Når informationen spredes mellem forskellige værktøjer, bliver det svært for både medarbejdere og AI-agenter at få et samlet billede af, hvad der er blevet sagt og besluttet. Resultatet er, at værdifuld tid går med at finde ud af, hvad der er blevet sagt og besluttet, og

TACTICAAI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 12:01:00 CEST | Press release

Collaboration brings together TACTICAAI’s operational decision-intelligence technology and NVIDIA AI capabilities to advance reasoning, autonomous analysis and video intelligence for real-world deployment TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 12:01:00 CEST | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye